[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].

Background null In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO). null Materials and methods null All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019...